Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings
Megan Calnan, Grace Blest‐hopley, Chris Busch, Mark J. Adams, Simon Ruffell, Theodore Piper, Leor Roseman, Hannes Kettner, Robin Carhart-Harris
Brain and Behavior July 1, 2025 DOI: 10.1002/brb3.70660 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 58 |
| Population | Military veterans |
| Interventions | Psilocybin Ayahuasca |
| Duration | Up to 4 weeks pre- and post-retreat |
| Topics | Anxiety Ayahuasca Psilocybin |
| Keywords | Mental health Depression economics Patient health questionnaire Clinical psychology Hallucinogen Psychotherapist Depressive symptoms |
| Citations | 4 |
| Key findings | Psilocybin and ayahuasca retreats significantly improved veterans' mental health and community reintegration, with the greatest improvements in depression and PTSD, and larger benefits for those with more severe initial symptoms. |
Abstract
Abstract Background : Military veterans are at risk of various mental health conditions, with profound implications for post‐deployment quality of life. Current treatment options encounter high dropout rates and non‐responsiveness, and overlook the importance of community building in veterans’ holistic recovery. Preliminary research suggests psychedelics offer therapeutic benefits for depression and post‐traumatic stress disorder (PTSD) in veterans. Integrating psychedelic therapies with a communal retreat setting could provide a more holistic framework for improving veterans’ well‐being. Objectives : To evaluate the effects of psychedelic retreats on mental health and community reintegration in veterans. Methods : Fifty‐eight veterans attended psilocybin or ayahuasca retreats. Participants completed eight mental health questionnaires (e.g. PTSD Checklist, PCL‐5; Patient Health Questionnaire, PHQ‐9), and the Military to Civilian Questionnaire (M2C‐Q) up to 4 weeks both pre‐ and post‐retreat. Paired t ‐tests analyzed changes in outcome responses between time points, and gender and substance‐specific analysis was conducted. Baseline scores were correlated with improvements in PCL‐5 and PHQ‐9 to investigate the relationship between initial symptom severity and percentage improvement following the retreat. Results : Significant improvements were found for all eight outcomes post‐retreat, with the greatest percentage improvements found for depression (PHQ‐9; 29.1%) and PTSD (PCL‐5; 26.1%). Veterans attending psilocybin retreats showed greater improvements in seven out of eight outcomes, whereas ayahuasca retreats demonstrated greater improvements in PCL‐5 scores for PTSD (ayahuasca: 26.4%; Psilocybin 24.8%). Male participants experienced greater improvements across all outcomes apart from the PCL‐5 for PTSD (Male: 24.1%; Female: 32.1%). Higher baseline scores on the PCL‐5 (PTSD) and PHQ‐9 (depression), indicating worse initial mental health, correlated with greater outcome improvements. Conclusions : This is the first study to investigate psychedelic retreats as a holistic therapy for veterans’ mental health alongside community reintegration. Psilocybin and ayahuasca retreats significantly improved veterans’ mental well‐being, quality of life, PTSD, anxiety, depression, sleep, concussion, and post‐deployment reintegration. Participants with more severe symptoms have the potential to benefit most from this intervention, with nuanced insight into improved outcomes based on gender and type of substance. Psychedelic retreats could provide a treatment framework to aid veterans’ recovery by addressing psychological well‐being, communal factors, and reintegration into civilian life.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Psilocybin or ayahuasca retreats significantly improved veterans' mental health outcomes, with the greatest improvements in depression and PTSD.
Synthesized
Comparable studies
Other observational and cohort studies on ayahuasca for anxiety, most cited first.
Citations in the library
Cited by 6
- Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats bioRxiv (Cold Spring Harbor Laboratory) October 14, 2025
- Effects of an international ceremonial ayahuasca retreat on the diversity and community composition of the human gut microbiome: A preliminary observational single-arm pre-post study Brain Behavior and Immunity Integrative July 1, 2026
- Retreat from Racism: A Psychedelic Group Experience for Racial Stress and Trauma Psychedelics July 1, 2026
- Psychedelics in Mental Health: Opportunities and Challenges. Brain and Behavior July 1, 2026
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
and 1 more in the library
Cites 48
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology April 26, 2017
and 43 more in the library